Michael Hartleib, MD, FRCPC

Kawartha Cardiology Clinical Trials
327 Charlotte Street, Suite 402

Peterborough, Ontario, Canada
K9J 0B2
705-775-0320

 

Speciality: Cardiology

 

 

Research Interests: Aneurysms, Angina, Arterial Thrombosis, Atherosclerosis, Cardiac Imaging, Cardiac Ischemia, Cardiac Transplantation, Cardiomyopathies, Cardiovascular Disease Prevention, Coronary Artery Disease, Dyslipidemia, Dysrhythmias, Heart Disease Reversal, Hyperlipidemia, Hypertension, Myocardial Infarction, Pacemakers, Peripheral Vascular Disease, Stress Testing, Syncope, Tachycardia

Dr. Michael Hartleib is a board certified Cardiologist with a fellowship from the Royal College of Physicians and Surgeons of Canada for both Adult Cardiology and Adult Critical Care Medicine. Dr. Hartleib completed his medical training at the University of Toronto including time as the Chief Cardiology Resident at Sunnybrook and Women’s College of Health Sciences Centre. Following his medical training Dr. Hartleib joined the Kawartha Cardiology Clinic as a Staff Cardiologist.

The Kawartha Cardiology Clinic focuses on atherosclerosis including angina, myocardial infarction, peripheral vascular disease, transient ischemic attack and strokes. In addition, the clinic focuses on hypertension with an active imaging department for stress testing, echo-doppler and carotid vascular imaging. The clinic also focuses on fitness, exercise and cardiac rehabilitation.  

The clinic provides cutting edge prevention and treatment options to the community including access to clinical trials. Dr. Hartleib is the President and leading Investigator of Kawartha Cardiology Clinical Trials. The clinical research team conduct clinical trials for cardiovascular disease, atherosclerosis, and many other conditions affecting the heart.

In addition to conducting clinical trials Dr. Hartleib is actively involved at the Peterborough Regional Health Centre as the Cardiology Section Lead, Staff Intensivist and Cardiologist. Due to his extensive clinical experience Dr. Hartleib is often invited to present to the medical community and lectures at Queen’s University as an Assistant Professor.

 

Click to view Dr. Michael Hartleib's Publications

Hartleib MC, Gooderham M. Top ten things rheumatologists should (and might not) know about inflammation and CV disease. CRAJ 2015 Fall; 25(3).

Fowler RA, Filate W, Hartleib M, Frost DW, Lazongas C, Hladunewich M. Sex and critical illness.  Curr Opin Crit Care 2009 Oct; 15(5):442-449. PMID: 19657274 / doi:10.1097/MCC.0b013e3283307a12

Hartleib M, Fowler R, Hladunewich M, Sibbald WJ. The influence of gender on enrollment into randomized controlled trials studying sepsis. American Thoracic Society 2004; A782.

Hartleib M, Sibbald WJ. “Re-organizing health care systems to optimize critical care outcomes”. In: DC Angus and J Carlet (Eds.), Surviving Intensive Care. Updates in Intensive Care and Emergency Medicine. Springer: (39):305-321, 2003.

Hartleib M, Sibbald WJ.  Simple interventions – significant impact.  Am J Respir Crit Care Med 2002 Feb 15; 165(4):434-435. PMID: # 11850331 / doi:10.1164/rccm.2112013

Hartleib M, Stewart TE. ARDS: New approaches in ventilatory management.  J Respir Disease 2001; 22(9):498-507.

Hartleib M. “Management of post-operative complications”. In: CS Dela Cruz and J Pressacco (Eds.), Pharmacological Treatment of Diseases. University of Toronto Press, 1997.

Hartleib M, Bitting S. “Orthopedics”. In: M Abraham and M Appleby (Eds.), 1998 MCCQE Review Notes and Lecture Series. University of Toronto, Faculty of Medicine: Toronto (14) 1997.

Hartleib M, Torun N, Sharpe J. The horizontal vestibulo-ocular reflex gain during active and passive head on body rotations. The University of Toronto Medical Journal 73(suppl.), 1996.

Hartleib M, Farber E. Induction of ribonucleotide reductase enzyme in regenerating hepatocytes may be sensitive to DNA damage within the cell. Proceedings of the American Association of Cancer Research. 36: 1078, 1995.

Hartleib M, Lee G, Farber E. Ribonucleotide reductase, a target for the mitoinhibitory effects of 2-AAF during the promotional phase of hepatocarcinogenesis. Proceedings of the American Association of Cancer Research. 36: 1003, 1994.

 

Copyright 2014 Probity Medical Research Inc. All Rights Reserved.

Login